India's Claris Viewed Takeover Target Because Of U.S. Injectables Shortage
This article was originally published in PharmAsia News
Executive Summary
Claris Lifesciences of India is being seen as a likely acquisition target as other firms seek entrée into the market of injectables in short supply in the U.S.